Scott Kopetz
321 posts
@skopetz
Colorectal cancer physician scientist, NCI Colon Task Force Chair, Professor, and Deputy Chair at The University of Texas, MD Anderson Cancer Center.
🩺 BREAKWATER update: First-line encorafenib/cetuximab + FOLFIRI showed higher response rates than chemo alone (64% vs 40%) in pts with BRAF V600E–mutant mCRC, with similar safety—"supporting a potential new SOC." #colorectalcancer @skopetz | #ASCOGI26 🔗 ascopost.com/news/january-2…
An example of the type of innovative adaptive design trials being supported by @ARPA_H ADAPT program. Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program cell.com/cancer-cell/fu… @skopetz @KimmieNgMD @GIcancerDoc @aparna1024
💥New paper out! We reanalyzed raw sequencing data from 18,558 standard-of-care Guardant360 ctDNA assays in advanced #colorectalcancer using a partner-agnostic fusion caller. 🧬 Fusions in 1.3% of patients 🧪 93% were subclonal — enriched after EGFR therapy 🔗 Clonal fusions linked to MSI-H tumors 💡 Subclonal fusions may signal impending acquired resistance to targeted therapies like EGFR inhibitors — offering a window for earlier intervention. 📄rdcu.be/exqmR Thanks to Andrew Pellatt for being a great co-fellow and letting me participate in this work along some of the defining leaders in CRC like @VanMorrisMD @skopetz @ryanhuey ! @GuardantHealth @TheGutOncLab @OncoAlert
Thank you for the opportunity to discuss this important topic in the treatment of patients with #CRC and thankful for the wonderful mentorship of @skopetz and @kanwal_raghav
🎉 Excited to stay on as Assistant Professor in GI Medical Oncology at @MDAndersonNews after graduation. Immensely grateful to my mentors & the support of my family and friends. Thankful to our patients and looking forward to working together to #EndCancer 🚀 #CRCSM #CCAhope
